Logo image
Back
Is OM-3 synergistic with GLP-2 in intestinal failure?
Journal article   Peer reviewed

Is OM-3 synergistic with GLP-2 in intestinal failure?

Avik Karmaker, Caitlyn M Costanzo and Marshall Z Schwartz
The Journal of surgical research, v 207, pp 7-12
Jan 2017
DOI: https://doi.org/10.1016/j.jss.2016.08.018
PMID: 27979490
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Animals Biomarkers - metabolism DNA - metabolism Drug Synergism Drug Therapy, Combination Fatty Acids, Omega-3 - pharmacology Fatty Acids, Omega-3 - therapeutic use Female Gastrointestinal Agents - pharmacology Gastrointestinal Agents - therapeutic use Glucagon-Like Peptide 2 - pharmacology Glucagon-Like Peptide 2 - therapeutic use Intestinal Absorption - drug effects Intestinal Mucosa - drug effects Intestinal Mucosa - metabolism Intestine, Small - drug effects Intestine, Small - metabolism Rats Rats, Sprague-Dawley Short Bowel Syndrome - drug therapy Short Bowel Syndrome - metabolism Treatment Outcome
Glucagon-like peptide-2 (GLP-2) is a known intestinal growth factor that enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR). Luminal omega-3 (OM-3) has been shown to have some growth factor properties. It is possible that their mechanisms of action differ. Thus, we hypothesized that administering these two substances together may have a synergistic effect. A total of 60 adult female Sprague-Dawley rats underwent 80% MSBR and divided as follows (n = 15/group): Saline (Control) + regular feeds; GLP-2 + regular feeds; Saline + OM-3 enriched feeds; and GLP-2 + OM-3 enriched feeds. Five animals per group were sacrificed at 7, 14, and 28 days. Small intestine mucosa was harvested. DNA and protein content were measured (mucosal mass markers) at all three time points. Galactose and Glycine absorption were measured (functional capacity markers) at 28 days. Statistical analysis was done by ANOVA with post hoc Tukey's HSD test. At all three time points, DNA was increased in all treatment groups compared to control (P < 0.05), but GLP-2 + OM-3 group did not have increased DNA content when compared to either treatments alone. At 7 and 14 d, all three treatment groups had increased protein content compared to control (P < 0.05). At 28 d, GLP-2 + OM-3 did not have increased protein content compared to control or individual treatments (P < 1.0). All three treatment groups had increased absorption of galactose and glycine compared to control (P < 0.05) but not each other. Individually, GLP-2 and OM-3 are very effective in enhancing the adaptive process by increasing mucosal mass and function, at all three time points. More importantly, clinically, GLP-2 and OM-3 increase substrate absorption in a rat model of intestinal failure. However, the combination is not synergistic.

Metrics

6 Record Views
2 citations in Web of Science
2 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#2 Zero Hunger
#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Surgery
Logo image